North Bristol NHS Trust

North Bristol NHS Trust have over 8,000 staff delivering healthcare across Southmead Hospital Bristol, Cossham Hospital, Bristol Centre for Enablement and within the local community of Bristol and South Gloucestershire.

Their aim is to provide their patients with best practice, high-quality care and treatment that is comparable to the best in the world. They want to care for our patients in a safe environment and ensure that everyone has an outstanding experience.

As part of a local healthcare system, North Bristol NHS Trust need to make the most efficient use of resources and work with partners to continuously improve the way they do things as they know this will lead to a better experience for patients and better clinical outcomes.

North Bristol NHS Trust want to be nationally recognised for their specialist services, leading regional provider networks and developing our services through a combination of clinical excellence, research and high-quality training.

Their vision has been defined as:

“We will realise the great potential of our organisation by empowering our skilled and caring staff to deliver high-quality, financially sustainable services in state-of-the-art facilities. Clinical outcomes will be excellent and with a spirit of openness and candour we will ensure an outstanding experience for our patients.”

Their values

Their values represent the way they do things and what they stand for.  By embedding these shared values in everything they do we will increase staff engagement, improve outcomes and create a positive experience for our patients.

• Working well together
• Putting the patient first 
• Recognising the person 
• Striving for excellence 

North Bristol NHS Trust and NCIMI

North Bristol NHS Trust has partnered with NCIMI (National Consortium of Intelligent Medical Imaging) work in mesothelioma developing artificial intelligence (AI) to assist clinic trial teams in monitoring treatment response through CT imaging.

ASSESS-meso, led by Professor Anna Bibby at Bristol with support of Professor Nick Maskell (University of Bristol Medical School), is a prospective, multicentre, observational cohort study that collects data and biological samples from mesothelioma patients, from the point of diagnosis until death. NCIMI, PREDICT-Meso and the ASSESS-Meso team from Biristol are collaborating to expand recruitment and evaluate the role of serial mesothelin as a response marker and prognostic indicator.

To learn more about them please visit their website.